| Structure | CCC=CCC1C(O)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C InChI=1S/C29H45NO7/c1-5-6-11-15-24-25(27(33)20-26(24)32)18-17-22(31)14-12-9-7-8-10-13-16-29(36)37-23(19-28(34)35)21-30(2,3)4/h6,8-12,17-18,22-26,31-32H,5,7,13-16,19-21H2,1-4H3  | 
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference | 
|---|
 | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 4.35 minutes | 32390414   |  | Predicted by Siyang on May 30, 2022 | 15.6039 minutes | 33406817   |  | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.05 minutes | 32390414   |  | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2646.6 seconds | 40023050   |  | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 179.2 seconds | 40023050   |  | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 216.3 seconds | 40023050   |  | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 184.3 seconds | 40023050   |  | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 168.1 seconds | 40023050   |  | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 621.5 seconds | 40023050   |  | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 451.7 seconds | 40023050   |  | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 624.5 seconds | 40023050   |  | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1542.4 seconds | 40023050   |  | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 537.0 seconds | 40023050   |  | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1779.2 seconds | 40023050   |  | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 389.7 seconds | 40023050   |  | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 426.8 seconds | 40023050   |  | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 372.9 seconds | 40023050   |  | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 152.0 seconds | 40023050   |  | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.0 seconds | 40023050   |  
 Predicted Kovats Retention IndicesUnderivatized| Metabolite | SMILES | Kovats RI Value | Column Type | Reference | 
|---|
 | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine | CCC=CCC1C(O)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 4363.1 | Standard polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine | CCC=CCC1C(O)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 2824.6 | Standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine | CCC=CCC1C(O)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 3614.6 | Semi standard non polar | 33892256   |  
 Derivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference | 
|---|
 | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,isomer #1 | CCC=CCC1C(O[Si](C)(C)C)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3715.4 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,isomer #2 | CCC=CCC1C(O)CC(=O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3753.9 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,isomer #3 | CCC=CCC1C(C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O | 3709.4 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TMS,isomer #4 | CCC=CCC1C(O)C=C(O[Si](C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3725.8 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,isomer #1 | CCC=CCC1C(O[Si](C)(C)C)CC(=O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3690.2 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,isomer #2 | CCC=CCC1C(C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C | 3688.4 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,isomer #3 | CCC=CCC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3717.7 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,isomer #4 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C)=C(O[Si](C)(C)C)CC1O | 3731.7 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TMS,isomer #5 | CCC=CCC1C(O)C=C(O[Si](C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3698.0 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C | 3677.8 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C | 3543.9 | Standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C | 4051.8 | Standard polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3661.5 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3441.8 | Standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 4017.2 | Standard polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,isomer #1 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)CC(=O)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3937.8 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,isomer #2 | CCC=CCC1C(O)CC(=O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 3980.3 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,isomer #3 | CCC=CCC1C(C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O | 3953.8 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,1TBDMS,isomer #4 | CCC=CCC1C(O)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3965.3 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,isomer #1 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)CC(=O)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4121.7 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,isomer #2 | CCC=CCC1C(C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C | 4112.1 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,isomer #3 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(O)CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 4160.2 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,isomer #4 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O | 4174.9 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,2TBDMS,isomer #5 | CCC=CCC1C(O)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4149.9 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C | 4257.4 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C | 4024.3 | Standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #1 | CCC=CCC1C(C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C | 4073.6 | Standard polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4271.2 | Semi standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 3889.8 | Standard non polar | 33892256   |  | (4Z,7Z,10S,11E)-10-Hydroxy-12-[(1S,2R,3R)-3-hydroxy-5-oxo-2-[(2Z)-pent-2-en-1-yl]cyclopentyl]dodeca-4,7,11-trienoylcarnitine,3TBDMS,isomer #2 | CCC=CCC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1C=CC(CC=CCC=CCCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4053.9 | Standard polar | 33892256   |  
  | 
|---|